BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Business

  Berkeley Lights Reports Third Quarter 2022 Financial Results

  Berkeley Lights, Inc., a leader in digital cell biology, reported financial results for the quarter ended September 30, 2022.

  November 8, 2022

   · 

  7 min read
• Biotech Bay

  Eiger BioPharmaceuticals to Participate in Upcoming November 2022 Investor Conferences

  Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, announced that members of its management team will participate in the following upcoming investor conferences.

  November 8, 2022

   · 

  1 min read
• Business

  Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

  Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2022, and recent corporate highlights.

  November 8, 2022

   · 

  10 min read
• Business

  Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

  Perimeter Medical Imaging AI, Inc. announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 15, 2022.

  November 8, 2022

   · 

  4 min read
• Business

  Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

  Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments.

  November 8, 2022

   · 

  7 min read
• Policy

  FDA Roundup: November 8, 2022

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

  November 8, 2022

   · 

  4 min read
• Pharm Country

  Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

  Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177 Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC).

  November 8, 2022

   · 

  5 min read